Last reviewed · How we verify
Sulpirid (SULPIRIDE)
Sulpiride works by blocking the action of carbonic anhydrase 6, an enzyme that helps regulate the balance of acid and base in the brain.
Sulpiride is a small molecule high-risk QT prolonging agent developed for the treatment of schizophrenia. It targets carbonic anhydrase 6, a key enzyme involved in the regulation of acid-base balance in the brain. Sulpiride is not FDA-approved, but it is used to treat schizophrenia in some countries. Its commercial status is unknown, and it has a half-life of 6.5 hours with 27% bioavailability. Key safety considerations include its potential to prolong the QT interval.
At a glance
| Generic name | SULPIRIDE |
|---|---|
| Drug class | High Risk QT Prolonging Agents |
| Target | Carbonic anhydrase 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Mechanism of action
Think of the brain as a delicate balance of acid and base. Carbonic anhydrase 6 helps regulate this balance by controlling the amount of acid and base in the brain. Sulpiride blocks this enzyme, which can help reduce symptoms of schizophrenia by changing the way the brain communicates.
Approved indications
- Schizophrenia
Common side effects
- Electrocardiogram QT prolonged
- Parkinsonism
- Torsade de pointes
- Suicide attempt
- Extrapyramidal disorder
- Fall
- Psychomotor retardation
- Neuroleptic malignant syndrome
- Cerebellar syndrome
- Serotonin syndrome
- Rhabdomyolysis
- Hypokalaemia
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- REALITY MONITORING (NA)
- The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement (NA)
- Dopamine and Cognition (NA)
- Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome (NA)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- The Effect of Antiemetics on Bowel Preparation Before Colonoscopy (PHASE4)
- Safety and Efficacy of Intrathecally Administered Magnesium Sulfate (NA)
- Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulpirid CI brief — competitive landscape report
- Sulpirid updates RSS · CI watch RSS